"The book was a delight to read and the editors must be congratulated on bringing together a diverse group of experts to describe both the pre-clinical and clinical aspects of this topical issue. (...) This book will more than fulfil the requirements of a clinician looking for information about the underlying neurobiology of pharmacotherapy." (Addiction)

• History of prevention of relapse.- How to measure relapse in animals.- How to measure relapse in humans.- Disulfiram (Antabuse®): the first medication to stop drinking.- Naltrexone: preclinical data.- Naltrexone: clinical data.- Acamprosate: preclinical data.- Acamprosate: clinical data.- Serotonergic compounds: preclinical data.- Serotonergic compounds: clinical data.- Opioidergic compounds: preclinical data.- Second generation opioidergic compounds: clinical data.- Dopaminergic compounds: preclinical data.- Dopaminergic compounds: clinical data.- Baclofen: preclinical data.- Baclofen: clinical data.- Cannabinoid receptor antagonists: a perspective.- Neuropeptide Y antagonists: a perspective.- Glutamatergic compounds: a perspective.- Future perspectives on relapse prevention.

"The book was a delight to read and the editors must be congratulated on bringing together a diverse group of experts to describe both the pre-clinical and clinical aspects of this topical issue. (...) This book will more than fulfil the requirements of a clinician looking for information about the underlying neurobiology of pharmacotherapy." (Addiction)

• History of prevention of relapse.- How to measure relapse in animals.- How to measure relapse in humans.- Disulfiram (Antabuse®): the first medication to stop drinking.- Naltrexone: preclinical data.- Naltrexone: clinical data.- Acamprosate: preclinical data.- Acamprosate: clinical data.- Serotonergic compounds: preclinical data.- Serotonergic compounds: clinical data.- Opioidergic compounds: preclinical data.- Second generation opioidergic compounds: clinical data.- Dopaminergic compounds: preclinical data.- Dopaminergic compounds: clinical data.- Baclofen: preclinical data.- Baclofen: clinical data.- Cannabinoid receptor antagonists: a perspective.- Neuropeptide Y antagonists: a perspective.- Glutamatergic compounds: a perspective.- Future perspectives on relapse prevention.

"The book was a delight to read and the editors must be congratulated on bringing together a diverse group of experts to describe both the pre-clinical and clinical aspects of this topical issue. (...) This book will more than fulfil the requirements of a clinician looking for information about the underlying neurobiology of pharmacotherapy." (Addiction)

• History of prevention of relapse.- How to measure relapse in animals.- How to measure relapse in humans.- Disulfiram (Antabuse®): the first medication to stop drinking.- Naltrexone: preclinical data.- Naltrexone: clinical data.- Acamprosate: preclinical data.- Acamprosate: clinical data.- Serotonergic compounds: preclinical data.- Serotonergic compounds: clinical data.- Opioidergic compounds: preclinical data.- Second generation opioidergic compounds: clinical data.- Dopaminergic compounds: preclinical data.- Dopaminergic compounds: clinical data.- Baclofen: preclinical data.- Baclofen: clinical data.- Cannabinoid receptor antagonists: a perspective.- Neuropeptide Y antagonists: a perspective.- Glutamatergic compounds: a perspective.- Future perspectives on relapse prevention.